ReviewEndocrine2021
Vitamin D in the Covid-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel.
Review in Endocrine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Effect of vitamin D supplementation on COVID-19 outcomes: an umbrella review of systematic reviews.Frontiers in nutrition · 2025Pooled it
- Vitamin D in Gut and Systemic Immune Tolerance and in Infections' Risk: An International Evidence-Based Consensus Statement.Reviews in endocrine & metabolic disorders · 2026Review
- Vitamin D in the elderly: the phil-rouge in preventing bone, muscle and adipose deterioration?Archives of endocrinology and metabolism · 2025Review
- Comparison of the role of vitamin D in normal organs and those affected by COVID-19.International journal of medical sciences · 2025Review
- Review
- Parkinson's Disease, SARS-CoV-2, and Frailty: Is There a Vicious Cycle Related to Hypovitaminosis D?Brain sciences · 2023Review
- Vitamin D3 and COVID-19 Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses.Antioxidants (Basel, Switzerland) · 2023Review
- Bone fragility during the COVID-19 pandemic: the role of macro- and micronutrients.Therapeutic advances in musculoskeletal disease · 2023Review
- The osteo-metabolic phenotype of COVID-19: an update.Endocrine · 2022Review
- Shared mechanisms and crosstalk of COVID-19 and osteoporosis via vitamin D.Scientific reports · 2022Article
- Revisiting the endocrine and metabolic manifestations of COVID-19 two years into the pandemic.Reviews in endocrine & metabolic disorders · 2022Review
- Antioxidant, anti-inflammatory and immunomodulatory roles of vitamins in COVID-19 therapy.European journal of medicinal chemistry · 2022Review
- Osteoporosis in Patients With Respiratory Diseases.Frontiers in physiology · 2022Review
- Vitamin D: A Potential Mitigation Tool for the Endemic Stage of the COVID-19 Pandemic?Frontiers in public health · 2022Review
- Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all?Reviews in endocrine & metabolic disorders · 2021Review
- Hypocalcemia in COVID-19 is associated with low vitamin D levels and impaired compensatory PTH response.Endocrine · 2021Article
- COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society.Endocrinology and metabolism (Seoul, Korea) · 2021Article
- COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology.Endocrine · 2021Article
- Is There a Crucial Link Between Vitamin D Status and Inflammatory Response in Patients With COVID-19?Frontiers in immunology · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin D (VITD) is a key hormone for bone health and has relevant extra-skeletal effects that might play a role in the prevention and treatment of COronaVIrus Disease 19 (COVID-19). Literature regarding this scenario is voluminous but controversial. Glucocorticoid Induced Osteoporosis Skeletal Endocrinology Group (G.I.O.S.E.G) has been present in the scientific debate about the use of VITD and has regularly interfaced national regulatory agencies to ensure appropriateness of its employment. Given the current pandemic and the questions on COVID-19 and VITD, G.I.O.S.E.G. appointed an expert panel to advise how to consider this issue best. The results of these deliberations are reported in the current recommendation paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.